XL880 (GSK1363089)

Development Status

Phase 2 clinical trials evaluating XL880 in papillary renal cell carcinoma, gastric cancer, and head and neck cancer are ongoing.

Description

XL880 is a potent inhibitor of MET and VEGFR2, which play synergistic roles in promoting tumor growth and angiogenesis. MET is mutationally activated in hereditary papillary renal cell carcinoma and in some non small-cell lung tumors, is activated or overexpressed in head and neck cancer, glioma, and other solid tumors, and is amplified in a subset of gastric and lung cancers.

Pursuant to a product development and commercialization agreement between Exelixis and GlaxoSmithKline, GlaxoSmithKline exercised its option to further develop and commercialize XL880.

Information on Clinical Trials

Information about ongoing clinical trials of Exelixis' investigational product candidates is available at ClinicalTrials.gov, a service of the U.S. National Institutes of Health. General information about clinical trials and issues related to participating in clinical trials also is available at ClinicalTrials.gov.

Related Publications

For publication information related to this compound, please see the Related Publications page.